[in Japanese]

View full abstract

Background: Studies of nintedanib (NTB) 200 mg/day in progressive fibrosing interstitial lung diseases are limited. 　Methods: We performed a retrospective study to compare efficacy and tolerability of NTB for two groups of patients with NTB at maintenance doses of 200 mg/day and 300 mg/day. 　Results: There were no significant differences in the discontinuation rate, annual decrease in effort lung capacity, the cumulative incidence of acute exacerbations, or survival between the two patients. 　Conclusion: The safety and efficacy of NTB 200 mg/day were not different from those of 300 mg/day, and future studies are warranted.

View full abstract

The patient was an 81-year-old woman with no smoking history. Since starting treatment with benralizumab for poorly controlled bronchial asthma with allergic bronchopulmonary aspergillosis (ABPA), her asthma was well controlled. However, two years after the initiation of benralizumab, her asthma and ABPA were exacerbated with increased peripheral blood eosinophil counts, which was speculated to be due to the decreased efficacy of benralizumab. After biologics were switched to dupilumab, both subjective symptoms and chest imaging improved. It was speculated that dupilumab may be effective for asthma with ABPA, even in benralizumab-resistant cases.

View full abstract